EGFR and EML4-ALK gene mutations in NSCLC: A case report of erlotinilb-resistant patient with both concomitant mutations
EGFR and EML4-ALK gene mutations in NSCLC: A case report of erlotinilb-resistant patient with both concomitant mutations
复制标题
DOI：
10.1016/j.lungcan.2010.11.014
复制
发表时间：
2011-02-01
期刊：
影响因子：
5.3
通讯作者：
Ardizzoni, A.
中科院分区：
文献类型：
--
作者：
Tiseo, M.;Gelsomino, F.;Ardizzoni, A.
融合基因EML4-ALK(棘皮微管相关蛋白样蛋白4基因和间变性淋巴瘤激酶基因)是最近发现的一种新的非小细胞肺癌(NSCLC)基因改变。EML4-ALK易位与特定的临床和病理特征相关，特别是缺乏EGFR和K-ras突变，并可能与对EGFR酪氨酸激酶抑制剂(TKIs)的耐药性有关。在这里，我们报告了一例伴有EGFR突变和ALK易位的患者对厄洛替尼耐药。考虑到这份报告，应该调查EGFR突变的NSCLC中EGFR-TKI耐药的不明原因病例的ALK状态。(C)2010爱思唯尔爱尔兰有限公司。保留所有权利。
The fusion gene EML4-ALK (echinoderm microtubule-associated protein-like 4 gene and the anaplastic lymphoma kinase gene) was recently identified as a novel genetic alteration in non-small cell lung cancer (NSCLC). EML4-ALK translocations correlate with specific clinical and pathological features, in particular lack of EGFR and K-ras mutations, and may be associated with resistance to EGFR tyrosine-kinase inhibitors (TKIs). Here, we report a case of a patient with a concomitant EGFR mutation and ALK translocation resistant to erlotinib. Considering this report, ALK status should be investigated in unexplained cases of EGFR-TKI-resistance of EGFR mutated NSCLCs. (C) 2010 Elsevier Ireland Ltd. All rights reserved.